Hepatitis E News and Research

RSS

Hepatitis E is a viral hepatitis (liver inflammation) caused by infection with a virus called hepatitis E virus (HEV).

One group of drugs that is effective in fighting HIV may also be promoting the death of sensory nerves in the skin

One group of drugs that is effective in fighting HIV may, paradoxically, also be promoting the death of sensory nerves in the skin, according to a study presented October 5, 2004, at the 129th annual meeting of the American Neurological Association in Toronto.

5 Oct 2004

Teva Pharmaceuticals granted final approval for Ribavirin capsules

Teva Pharmaceutical Industries has announced that the U.S. Food and Drug Administration has granted final approval for the Company’s ANDA for Ribavirin Capsules, 200 mg. Shipment of this product is expected to begin immediately.

5 Oct 2004

Bristol-Myers Squibb submits New Drug Application to the U.S. Food and Drug Administration for entecavir

Bristol-Myers Squibb has announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B.

4 Oct 2004

Chiron grants a non-exclusive license to the German Red Cross

Chiron Corporation has announced that it has granted a non-exclusive license to the Blood Transfusion Centers of the German Red Cross (Blutspendediensten des Deutsche Rotes Kreuz, or DRK) for use of the company's HIV-1 and hepatitis C virus (HCV) technology for use in molecular probe "home brew" blood screening.

4 Oct 2004

Circulation of ‘disaster myths’ in Haiti could hinder appropriate disposal of bodies

Myths about the infectious disease threat posed by dead bodies could lead to insensitive and inappropriate treatment of victims’ bodies following the floods in Haiti, and need to be checked, according to a public health researcher who has studied the potential risks at length.

30 Sep 2004

New combination of drugs results in fewer incidences of rejection in liver transplant patients

“The big advantage [of this combination of drugs] is that the incidence of rejection is significantly decreased,” he says. “These results could change the standard of care for liver transplant recipients.”

23 Sep 2004

Research to halt the progress of chronic liver disease

A University of Queensland researcher is working to halt the progress of chronic liver disease, which affects a quarter of million Australians.

22 Sep 2004

Edible vaccine for HIV AIDS

Scientists from Novosibirsk are engaged in the development of an unusual vaccine which, apart from being less expensive to produce, safe and painless to administer, is also edible.

22 Sep 2004

New recommendations which will help pre-empt drinking water contamination

Ensuring drinking water is safe is a challenge in every part of the world, from water piped into people's homes, to rural wells and water provided to refugee camps in an emergency.

22 Sep 2004

NIH opens new hospital totally dedicated to clinical research

This new hospital totally dedicated to clinical research — research involving patients — is the most significant addition to the NIH campus in more than 50 years and provides a unique opportunity for scientists, clinicians, and patients to study and conquer both chronic and acute disease in the 21st century.

22 Sep 2004

Liver cancer, cirrhosis of the liver and other diseases related to hepatitis B infection will continue to increase

Liver cancer, cirrhosis of the liver and other diseases related to hepatitis B infection will continue to kill people in the prime of life and burden health systems with chronically sick people unless childhood immunization against hepatitis B is stepped up

20 Sep 2004

Urgent measures need to be taken to protect the public from contaminated blood transfusions

In the Western Pacific Region, transmission of HIV/AIDS and other infections such as hepatitis B and C through blood transfusion remains a serious threat. It is particularly acute in areas where prevalence of these diseases is high and access to safe blood is limited.

16 Sep 2004

Severe hepatitis C recurrence is more common in transplants from living donors

Hepatitis C recurs with severity more often in individuals who receive liver transplants from living donors compared with those who get transplants from cadavers, according to a new study published in the September 2004 issue of Hepatology.

9 Sep 2004

Long-term outcomes for liver transplantation due to hepatitis C

A new study on liver transplants necessitated by the hepatitis C virus (the most common indication for this type of transplant) found that long-term outcomes are similar to patients receiving transplants due to other diseases.

8 Sep 2004

Sinovac completes dosing in phase 1 human clinical testing of SARS vaccine

Sinovac Biotech Ltd. has announced that all 36 subjects of the Phase I human clinical trial for its inactivated SARS vaccine have now been vaccinated with two doses of either SARS vaccine or placebo.

7 Sep 2004

The Australian Government response to Senate inquiry into hepatitis C and blood supply

Although the Inquiry found that decision makers had made reasonable decisions in the 80s, based on the evidence available, medically acquired hepatitis C has hurt many people.

30 Aug 2004

Researchers have identified multiple changes in the gene-expression patterns of cells involved with tumor progression in liver cancer patients

Virginia Commonwealth University researchers have identified multiple changes in the gene-expression patterns of cells involved with tumor progression in liver cancer patients and in those with cirrhosis, which may help scientists predict a person’s risk of developing primary liver cancer.

25 Aug 2004

Surprise finding could lead to hepatitis C vaccine

New research from the University of New South Wales shows some people may repeatedly be able to clear hepatitis C virus from their bodies, without any biological traces of the potentially serious infection.

23 Aug 2004

Peginterferon and Ribavirin combination promising for those with HIV and HCV

Since the introduction of highly active combination drug therapy for HIV, liver failure attributable to infection with the hepatitis C virus (HCV) has become a leading cause of death among those infected with the virus that causes AIDS.

22 Aug 2004

Existing hepatitis drug could lead to the development of new drugs for the treatment of anthrax

Thanks to new screening tools, and some luck, researchers at the University of Chicago have discovered three unrelated compounds that inhibit the two toxins – edema factor and lethal factor -- that have made anthrax one of the most feared of potential bioterror agents.

21 Aug 2004

Hepatitis E News and Research

Further Reading

One group of drugs that is effective in fighting HIV may also be promoting the death of sensory nerves in the skin

Teva Pharmaceuticals granted final approval for Ribavirin capsules

Bristol-Myers Squibb submits New Drug Application to the U.S. Food and Drug Administration for entecavir

Chiron grants a non-exclusive license to the German Red Cross

Circulation of ‘disaster myths’ in Haiti could hinder appropriate disposal of bodies

New combination of drugs results in fewer incidences of rejection in liver transplant patients

Research to halt the progress of chronic liver disease

Edible vaccine for HIV AIDS

New recommendations which will help pre-empt drinking water contamination

NIH opens new hospital totally dedicated to clinical research

Liver cancer, cirrhosis of the liver and other diseases related to hepatitis B infection will continue to increase

Urgent measures need to be taken to protect the public from contaminated blood transfusions

Severe hepatitis C recurrence is more common in transplants from living donors

Long-term outcomes for liver transplantation due to hepatitis C

Sinovac completes dosing in phase 1 human clinical testing of SARS vaccine

The Australian Government response to Senate inquiry into hepatitis C and blood supply

Researchers have identified multiple changes in the gene-expression patterns of cells involved with tumor progression in liver cancer patients

Surprise finding could lead to hepatitis C vaccine

Peginterferon and Ribavirin combination promising for those with HIV and HCV

Existing hepatitis drug could lead to the development of new drugs for the treatment of anthrax

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News